Gerontology/Geriatrics Topic Homepage

Prostate Cancer Learning Hub

,Prostate Cancer Learning Hub

Prostate cancer is the third most frequently diagnosed cancer in Europe and the most common cancer among European men,1 making it a major cause of morbidity. Risk factors for prostate cancer include, increasing age, genetic susceptibility, glucose intolerance and environmental factors.2

The Prostate Cancer Learning Hub has been designed with the busy healthcare professional in mind. The resource conveniently organises a range of up-to-date education content, reference materials and decision support tools, all focussing on prostate cancer.

The disease awareness section provides you with access to a Prostate Cancer Knowledge Centre, which has been developed to provide you with easy to digest best practice guidance for the treatment and management of patients with prostate cancer. In addition access to editorials of key journal publications, an events calendar, video channel, patient materials and interactive healthcare professionals tools are also available.

References

  1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-1403. EUCAN fact sheet. Estimated incidence, mortality & prevalence, 2012.
  2. Tewari R, Rajender S, Natu SM et al. Diet, obesity, and prostate health: are we missing the link? J Androl 2012;33:763-776.

     

COPD

,COPD Knowledge Centre

Patients with Chronic Obstructive Pulmonary Disease (COPD) will rank as the fifth leading cause of disability in 2030, accounting for almost 4% of total disability-adjusted life years (DALYs) lost worldwide.1 Many patients with COPD report that the symptoms of COPD are at their worst in the morning, having a major impact on their quality of life.2,3 For this reason effective management of morning symptoms has to be a major treatment goal.

The COPD Knowledge Centre has been designed to provide you, as a healthcare professionals, with free access to educational disease awareness. This includes information on the epidemiology, pathophysiology, and symptoms of COPD and the latest best practice guidelines for the diagnosis, treatment and management for the disease.

COPD specific resources such as videos, guidelines, infographics, materials for your patients, upcoming events and useful websites are available for you. In addition educational slide decks and an interactive presentation from ATS 2013 are also available.


References

  1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and prevention of COPD. 2014
  2. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009;25: 2043-2048. 
  3. Partridge MR et al. Curr Med Res Opin 2012;28:1405. [Erratum].

Anti-Infectives Knowledge Network CDI

,AIKN CDI

The Anti-Infectives Knowledge Network – Clostridium difficile infections (AIKN-CDI), an initiative by Astellas Pharma EMEA, shares the expertise and experience of thought leaders in the area of anti-infectives.

Recent content updates include:

  • Presentation slides from recent congresses including ECCMID, EBMT and ISICEM 2015
  • News articles from key industry thinkers located within the ‘CDI perspectives’ section
  • An animation sequence showing gut microflora and the effects of antibiotics on CDI
  • Opportunity to participate in the second round of the largest ever clinician consensus report through completing a questionnaire. Subsequent recommendations will be made based on the data collected from this questionnaire

Please remember to return often to read updated news, clinical insights, and essential information from the latest congresses.

May 2015 MYC/15/0020/EUb

Anti-Infectives Knowledge Network IFI

,AIKN IFI

The Anti-Infectives Knowledge Network – Invasive Fungal Infections (AIKN-IFI), an initiative by Astellas Pharma EMEA, assembles the experience and expertise of a number of thought leaders in the area of anti-infectives, with particular focus on invasive fungal infections.

This free resource is regularly updated with congress highlights, industry reports, policy changes, clinical guidelines and downloadable material (e.g. presentation slides) from major medical events.

The latest update to the AIKN-IFI is a summary of recent ESCMID-led recommendations into the prevention and management of infections in solid organ transplantation. These new recommendations are available in the guidelines section.

May 2015 MYC/15/0020/EUb

Heart Failure

Heart Failure

Heart Failure is a progressive chronic disorder that results in the inability of the heart to pump blood efficiently to the body’s tissues.

Chronic heart failure is an increasing public health problem; the growing prevalence in industrialised countries means that 1-2% of the adult population of these countries are now thought to have chronic heart failure.1-3 Estimates suggest that the prevalence in Europe, USA and Japan could increase by approximately 16.5% over the next ten years.4

The prevalence of post-myocardial infarction heart failure is less well known as it is difficult to distinguish between pre-existing and incident heart failure. However current estimates suggest that approximately 1 in 5 patients hospitalised with an acute coronary syndrome either present with heart failure or develop heart failure during their hospital stay.5

Many of the signs and symptoms of heart failure are non-specific and vary in severity depending on the disease class. The most common of these are breathlessness, fatigue, exercise intolerance, and fluid retention as evidenced by ankle swelling, peripheral oedema, and an elevated jugular venous pressure.6

Due to the non-specific nature of symptoms, the diagnosis of heart failure can be difficult. Tests can include echocardiogram, ECG, chest X-ray, laboratory tests. Following a positive diagnosis heart failure is classified into functional classes that relate to disease severity.

Management of heart failure involves lifestyle modifications, pharmacological treatment and occasionally surgery. In patients with chronic heart failure, optimal therapy involves treatment with diuretics, ACE inhibitors, certain β-blockers and a mineralocorticoid receptor antagonist.

The Heart Failure Knowledge Centre brings together current information related to chronic heart failure and post-myocardial infarction, including:

  • Epidemiology
  • Symptoms and Diagnosis
  • Classification
  • Treatment Options
Enter the Heart Failure Knowledge Centre

References

  1. Zannad F, et al. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Journal of the American College of Cardiology 1999; 33(3):734-742.
  2. Cowie MR, et al. The epidemiology of heart failure. European Heart Journal 1997;18(2):208-225.
  3. Mosterd A, Hoes A. Clinical epidemiology of heart failure. Heart 2007; 93:1137-1146.
  4. Decision Resources. Chronic Heart Failure. Cardium Study No.4 A Pharmacor Service. 2008.
  5. Steg PG, Dabbous OH, et al. Determinants and prognostic impact of heart failure complicating acutecoronary syndromes. Observations from the Global Registry of Acute Coronary Events (GRACE). Circulation2004;109:494-9.
  6. NICE Clinical Guideline No 108. Chronic Heart Failure. National clinical guideline for diagnosis and management in primary and secondary care. 2010.

Latest News

Medical Videos

Ask The Geriatrician - The Physiology of Ageing
Ask The Geriatrician - The Physiology of Ageing

Recent Drug Updates

Medical Journal Abstracts on Gerontology/Geriatrics

Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III colorectal cancer patients (LC-ACEC): study protocol for a randomized controlled trial.

Fri 29 May 2015 -  Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III colorectal cancer patients (LC-ACEC): study protocol for a randomized controlled trial.

BACKGROUND: Over half of the patients were diagnosed with colorectal cancer after 70 years of age. The choice of the most suitable chemotherapy strategy is the major challenge for elderly patients. ...

The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies.

Thu 16 Apr 2015 -  The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies.

CONTEXT: Alendronate may relate to the incidence of cancers, especially esophageal and colon cancer. But the results are inconsistent in different studies. OBJECTIVE: To quantify the association ...

Clinical Guidelines

Peri-operative care of the elderly 2014

Jan 2014

This guideline is specific to the role of anaesthesia within the multidisciplinary peri-operative..

... care given to elderly surgical patients.

Time to Redefine PD? Introductory Statement of the MDS Task Force on the Definition of Parkinson’s Disease

Dec 2013

This review is intended as an introductory discussion article; it is not the final word on disease..

... definition, but rather an opening of dialog. Each section will start by presenting conversational-style informal minivignettes (in italics) that summarize what clinicians or researchers often mention when pointing out problems with the current PD definition. Both sides of each issue are then discussed, followed by proposals for moving forward. Finally, we will discuss the need for new diagnostic criteria for PD.

Online CME

e-LfH Dementia

Dementia is becoming increasingly prevalent, both due to our ageing population and improved recognition of the condition. However, the nature of dementia means that managing the condition can pose unique...

Anaemia in old age: common presentations

After completing this module you should know how to: take a history and examine an elderly patient with anaemia, diagnose the common causes of anaemia in old age, and treat...

Clinical Trials

Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (FLUGAZA)

Wed 10 Dec 2014

The hypothesis is that the replacement of the standard fludarabine and cytarabine based therapy by azacytidine could result in an improvement of RFS and OS rates in the experimental arm. To fulfill ...

Neuromuscular Control in Knee Osteoarthritis (NEKO)

Tue 02 Dec 2014

Arthritis is one of the most prevailing causes of disability with knee osteoarthritis (KOA) the most common form. The lifetime risk of developing symptomatic KOA by the age of 85 years is 44.7%, ...

Back to top